Radiation-enhanced endostatin gene expression and effects of combination treatment

Technology in Cancer Research and Treatment

Volumn 4, Issue 2, 2005, Pages 193-202

  Luo, Xian ^a   Andres, Melba L ^a   Timiryasova, Tatyana M ^a   Fodor, Istvan ^a   Slater, James M ^a   Gridley, Daila S ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti angiogenic factors; Endostatin; Gene therapy; Ionizing radiation; Lewis lung carcinoma; Lung cancer

Indexed keywords

ENDOSTATIN; PLASMID VECTOR;

ANALYSIS OF VARIANCE; ANIMAL CELL; CELL LINE; CELL TYPE; CONFERENCE PAPER; CULTURE MEDIUM; DNA SYNTHESIS; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL ELECTROPHORESIS; GENE EXPRESSION; GENE THERAPY; IMMUNOCYTOCHEMISTRY; LEWIS CARCINOMA; LUNG CANCER; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; RADIATION; RADIATION EXPOSURE; UMBILICAL VEIN; WESTERN BLOTTING;

EID: 17644425553     PISSN: 15330346     EISSN: None     Source Type: Journal    
DOI: 10.1177/153303460500400208     Document Type: Conference Paper

References (62)

1. Dosoretz, D. E., Galmarini, D., Rubinstein, J. H., Katin, M. J., Blitzer, P. H., Salenius, S. A., Dosani, R. A., Rashid, M., Mestas, G., Hannan, S. E. et al. Local Control in Medically Inoperable Lung Cancer: An Analysis of its Importance in Outcome and Factors Determining the Probability of Tumor Eradication. Int. J. Radiat. Oncol. Biol. Phys. 27, 507-516 (1993).
2. Dosoretz, D. E., Katin, M. J., Blitzer, P. H., Rubenstein, J. H., Salenius, S., Rashid, M., Dosani, R. A., Mestas. G., Diegel, A. D., Chadha, T. T., et al. Radiation Therapy in the Management of Medically Inoperable Carcinoma of the Lung: Results and Implications for Future Treatment Strategies. Int. J. Radiat. Oncol. Biol. Phys. 24, 3-9 (1992).
3. Abid, S. H., Malhotra, V., and Perry, M. C. Radiation-induced and Chemotherapy-induced Pulmonary Injury. Curr Opin Oncol. 13, 242-248 (2001).
4. Simon, M., Argiris, A., and Murren, J. R. Progress in the Therapy of Small Cell Lung Cancer. Crit. Rev. Oncol. Hematol. 49, 119-133 (2004).
5. Folkman, J. Antiangiogenic Therapy, in Principles and Practice of Oncology, pp. 3075-3085. Eds., Devita, V. T., Hellman, S., and Rosenberg, S.A. Philadelphia, PA, Lippincott-Raven Publishers (1997).
6. Gridley, D. S. and Slater, J. M. Combining Gene Therapy and Radiation Against Cancer. Curr. Gene Ther. 4, 231-248 (2004).
7. Plum, S. M., Hanson, A. D., Volker, K. M, Vu, H. A., Sim, B. K., Fogler, W. E., and Fortier, A. H. Synergistic Activity of Recombinant Human Endostatin in Combination with Adriamycin: Analysis of In Vitro Activity on Endothelial Cells and In Vivo Tumor Progression in an Orthotopic Murine Mammary Carcinoma Model. Clin. Cancer Res. 9, 4619-4626 (2003).
8. Siemann, D. W., Warrington, K. H., and Horsman, M. R. Targeting Tumor Blood Vessels: An Adjuvant Strategy for Radiation Therapy. Radiother. Oncol. 57, 5-12 (2000).
9. Teh, B. S., Aguilar-Cordova, E., Vlachaki, M. T., Aguilar, L., Mai, W. Y., Caillouet, J., Davis, M., Miles, B., Kadmon, D., Ayala, G., Lu, H. H., Chiu, J. K., Carpenter, L. S., Woo, S. Y., Grant, W. H. 3rd, Wheeler, T., Thompson, T. C. and Butler, E. B. Combining Radiotherapy with Gene Therapy (From the Bench to the Bedside): A Novel Treatment Strategy for Prostate Cancer. Oncologist 7, 458-466 (2002).
10. Browder, T., Butterfield, C. E., Kraling, B. M., Shi, B., Marshall, B., O'Reilly, M. S., and Folkman, J. Anti-angiogenic Scheduling of Chemotherapy Improves Efficacy Against Experimental Drug-resistant Cancer. Cancer Res. 60, 1878-1886 (2000).
11. Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J, Bohlen, P., Kerbel, R. S. Continuous Low-dose Therapy with Vinblastine and VEGF receptor-2 Antibody Induces Sustained Tumor Regression Without Overt Toxicity. J. Clin. Invest. 105, R15-24 (2000).
12. Kozin, S. V., Boucher, Y., Hicklin, D. J., Bohlen, P., Jain, R. K., and Suit, H. D. Vascular Endothelial Growth Factor-receptor-2-blocking Antibody Potentiates Radiation-induced Long-term Control of Human Tumor Xenografts, Cancer Res. 61, 39-44 (2001).
13. Teicher, B. A. A Systems Approach to Cancer Therapy. Cancer Metastasis Rev. 15, 247-272 (1996).
14. Rakesh, K. J. Normalizing Tumor Vasculature with Anti-angiogenic Therapy: A New Paradigm for Combination Therapy. Nature Medicine 7, 987-989 (2001).
15. Lee, C. G., Heijn, M., di Tomaso, E., Griffon-Etienne, G., Ancukiewicz, M., Koike, C., Park, K. R., Ferrara, N., Jain, R. K., Suit, H. D., and Boucher, Y. Anti-vascular Endothelial Growth Factor Treatment Augments Tumor Radiation Response under Normoxic or Hypoxic Conditions. Cancer Res. 60, 5565-5570 (2000).
16. Hansen-Algenstaedt, N., Stoll, B. R., Padera, T. P., Dolmans, D. E., Hicklin, D. J., Fukumura, D., and Jain, R. K. Tumor Oxygenation During Vascular Endothelial Growth Factor Receptor-2 Blockade, Hormone Ablation, and Chemotherapy. Cancer Res. 60, 4556-4560 (2000).
17. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R, and Folkman, J. Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth. Cell 88, 277-285 (1997).
18. Gottlieb, S. Endostatin May Stop the Progression of Atherosclerosis. Br. Med. J. 318, 1830B (1999).
19. Larsson, H., Rreuger, J., Salmivirta, M., Claesson-Welsh, L., Lindahl, U., and Timpl, R. Structural Basis and Potential Role of Heparin/Heparan Sulfate Binding to the Angiogenesis Inhibitor Endostatin. EMBO J. 18, 6240-6248 (1999).
20. Dhanabal, M., Ramchandran, R., Waterman, M. J., Lu, H., Knebelmann, B., Segel, M., and Sukhatme, V. P. Endostatin Induces Endothelial Cell Apoptosis. J. Biol. Chem. 274, 11721-11726 (1999).
21. Nguyen, J. T., Wu, P., Clouse, M. E., Hlatky, L., and Terwilliger, E. F. Adenoassociated Virus-mediated Delivery of Antiangiogenic Factors as an Antitumor Strategy. Cancer Res. 58, 5673-5677 (1998).
22. Tanaka, T., Cao, Y., Folkman, J., and Fine, H. A. Viral Vector-targeted Antiangiogenic Gene Therapy Utilizing an Angiostatin Complementary DNA. Cancer Res. 58, 3362-3369 (1998).
23. Cavazzana-Calvo, M., Thrasher, A., and Mavilio, F. The Future of Gene Therapy. Nature 427, 779-781 (2004).
24. Kim, J. M., Jeong, J. G., Ho, S. H., Hahn, W., Park, E. J., Kim, S., Yu, S. S., Lee, Y. W., and Kim, S. Protection Against Collagen-induced Arthritis by Intramuscular Gene Therapy with an Expression Plasmid for the Interleukin-1 Receptor Antagonist. Gene Ther. 10, 1543-1550 (2003).
25. Imboden, M., Shi, F., Pugh, T. D., Freud, A. G., Thom, N. J., Hank, J. A., Hao, Z., Staelin, S. T., Sondel, P. M., and Mahvi, D. M. Safety of Interleukin-12 Gene Therapy Against Cancer: A Murine Biodistribution and Toxicity Study. Hum. Gene. Ther. 14, 1037-1048 (2003).
26. Ma, C. H., Zhang, Y., Wang, X. Y., Gao, L. F., Liu, H., Guo, C., Liu, S. X., Cao, Y. L., Zhang, L. N., and Sun, W. S. Human Endostatin Gene Transfer, Either Naked or With Liposome, has the Same Inhibitory Effect on Growth of Mouse Liver Tumor Cells In Vivo. World J Gastroenterol. 10, 2874-2877 (2004).
27. Sheay, W., Nelson, S., Martinez I., Chu, T. H., Bhatia, S., and Dornburg, R. Downstream Insertion of the Adenovirus Tripartite Leader Sequence Enhances Expression in Universal Eukaryotic Vectors. BioTechniques 15, 856-862 (1993).
28. Merrick, W. C. Mechanism and Regulation of Eukaryotic Protein Synthesis. Microbiol Rev. 56, 291-315 (1992).
29. Baher, A. G., Andres, M. L., Folz-Holbeck, J., Cao, J. D., and Gridley, D. S. A Model Using Radiation and Plasmid-mediated Tumor Necrosis Factor-α Gene Therapy for Treatment of Glioblastoma. Anticancer Res. 19, 2917-2924 (1999).
30. Li, J., Andres, M. L., Fodor, I., Nelson, G. A., and Gridley, D. S. Evaluation of pGL1-TNF-α Therapy in Combination with Radiation. Oncol Res. 10, 379-387 (1999).
31. Yamaguchi, N., Anand-Apte, B., Lee, M., Sasaki, T., Fukai, N., Shapiro, R., Que, I., Lowik, C., Timp, R., and Olen, B. R. Endostatin Inhibits VEGF-induced Endothelial Cell Migration and Tumor Growth Independently of Zinc Binding. EMBO J. 18, 4414-4423 (1999).
32. Blezinger, P., Wang, J., Gondo, M., Quezada, A., Mehrens, D., French, M., Singhal, A., Sullivan, S., Rolland, A., Ralston, R., and Min, W. Systemic Inhibition of Tumor Growth and Tumor Metastases by Intramuscular Administration of the Endostatin Gene. Nat. Biotechnol. 17, 343-348 (1999).
33. Blezinger, P., Yin, G., Xie, L., Wang, J., Martar, M., Bishop, J. S., and Min, W. Intravenous Delivery of an Endostatin Gene Complexed in Cationic Lipid Inhibits Systemic Angiogenesis and Tumor Growth in Murine Models. Angiogenesis 3, 205-210 (1999).
34. Chen, Q. R., Kumar, D., Stass, S. A., and Mixson, A. J. Liposomes Complexed to Plasmids Encoding Angiostatin and Endostatin Inhibit Breast Cancer in Nude Mice. Cancer Res. 59, 3308-3312 (1999).
35. Yoon, S. S., Eto, H., Lin, C. M., Nakamura, H., Pawlik, T. M., Song, S. U., and Tanabe, K. K. Mouse Endostatin Inhibits the Formation of Lung and Liver Metastases. Cancer Res. 59, 6251-6256 (1999).
36. Dhanabal, M., Ramchandran, R., Simons, M., and Sukhatme, V. P. Cloning, Expression, and In Vitro Activity of Human Endostatin. Biochem. Biophy. Res. Commun. 258, 354-352 (1999).
37. Sasaki, T., Fukai, N., Mann, K., Gohring, W., Olsen, B. R., and Timpl, R. Structure, Function, and Tissue Forms of the C-terminal Globular Domain of Collagen XVIII Containing the Angiogenesis Inhibitor Endostatin. EMBO J. 17, 4249-4256 (1998).
38. Taddei, L., Chiarugi, P., Brogelli, L., Cirri, P., Magnelli, L., Raugei, G., Ziche, M., Granger, H. J., Chiarugi, V., and Ramponi, G. Inhibitory Effect of Full-length Human Endostatin on In Vitro Angiogenesis. Biochem. Biophys. Res. Comm. 263, 340-345 (1999).
39. Dixelius, J., Cross, M., Matsumoto, T., Sasaki, T., Timpl, R., and Claesson-Welsh, L. Endostatin Regulates Endothelial Cell Adhesion and Cytoskeletal Organization. Cancer Res. 62, 1944-1947 (2002).
40. Dixelius, J., Larsson, H., Sasaki, T., Holmqvist, K., Lu, L., Engstrom, A., Timpl, R., Welsh, M., and Claesson-Welsh, L. Endostatin-induced Tyrosine Kinase Signaling Through the Shb Adaptor Protein Regulates Endothelial Cell Apoptosis. Blood 95, 3403-3411 (2000).
41. Zetter, B. R. Angiogenesis and Tumor Metastasis. Annu. Rev. Med. 49, 407-424 (1998).
42. Wilson, R. F., Morse, M. A., Pei, P., Renner, R. J., Schuller, D. E., Robertson, F. M., and Mallery, S. R. Endostatin Inhibits Migration and Invasion of Head and Neck Squamous Cell Carcinoma Cells. Anticancer Res. 23, 1289-1295 (2003).
43. Hajitou, A., Grignet, C., Devy, L., Berndt, S., Blacher, S., Deroanne, C. F., Bajou, K., Fong, T., Chiang, Y., Foidart, J. M., and Noel, A. The Antitumoral Effect of Endostatin and Angiostatin is Associated with a Down-regulation of Vascular Endothelial Growth Factor Expression in Tumor Cells. FASEB J. 16, 1802-1804 (2002).
44. Dixelius, J., Cross, M. J., Matsumoto, T., and Claesson-Welsh, L. Endostatin Action and Intracellular Signaling: Beta-catenin as a Potential Target? Cancer Lett. 196, 1-12 (2003).
45. Streck, C., Zhang, Y., Zhou, J., Ng, C. Y., and Davidoff, A. Metastasis and Angiogenesis. Cancer Treat Res. 117, 285-304 (2004).
46. Dkhissi, F., Lu, H., Soria, C., Opolon, P., Griscelli, F., Liu, H., Khattar, P., Mishal, Z., Perricaudet, M., and Li, H. Endostatin Action and Intracellular Signaling: Beta-catenin as a Potential Target? Cancer Lett. 196, 1-12 (2003).
47. Eder, J. P. Jr., Supko, J. G., Clark, J. W., Puchalski, T. A., Garcia-Carbonero, R., Ryan, D. P., Shulman, L. N., Proper, J., Kirvan, M., Rattner. B., Connors, S., Keogan, M. T., Janicek, M. J., Fogler, W. E., Schnipper, L., Kinchla, N., Sidor, C., Phillips, E., Folkman, J., and Kufe, D. W. Phase I Clinical Trial of Recombinant Human Endostatin Administered as a Short Intravenous Infusion Repeated Daily. J. Clin. Oncol. 20, 3772-3784 (2002).
48. Fogler, W. E., Song, M., Supko, J. G. et al. Recombinant Human Endostatin Demonstrates Consistent and Predictable Pharmacokinetics Following Intravenous Bolus Administration to Cancer Patients (Abstract). Proc ASCO. 19, 274 (2001).
49. Herbst, R. S., Mullani, N. A., Davis, D. W., Hess, K. R., McConkey, D. J., Charnsangavej, C., O'Reilly, M. S., Kim, H. W., Baker, C., Roach, J., Ellis, L. M., Rashid, A., Pluda, J., Bucana, C., Madden, T. L., Tran, H. T., Abbruzzese, J. L. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol. 20, 3804-3814 (2002).
50. Kerbel, R. and Folkman, J. Clinical Translation of Angiogenesis Inhibitors (Review). Nat. Rev. Cancer 2, 727-739 (2002).
51. Kim, E. S. and Herbst, R. S. Angiogenesis Inhibitors in Lung Cancer. Curr. Oncol. Rep. 4, 325-333 (2002).
52. Kisker, O., Becker, C. M., Prox, D., Fannon, M., D'Amato, R., Flynn, E., Fogler, W. E., Sim, B. K., Allred, E. N., Pirie-Shepherd, S. R., and Folkman, J. Continuous Administration of Endostatin by Intraperitoneally Implanted Osmotic Pump Improves the Efficacy and Potency of Therapy in a Mouse Xenograft Tumor Model. Cancer Res. 61, 7669-7674 (2001).
53. Gridley, D. S., Li, J., Kajioka, E. H., Andres, M. L., Moyers, M. F., and Slater, J. M. Combination of pGL1-TNF-α Gene and Radiation (Proton and γ-ray) Therapy Against Brain Tumor. Anticancer Res. 20, 4195-4203 (2000).
54. Gridley, D. S., Baer, J. R., Cao, J. D., Miller, G. M., Kim, D. W., Timiryasova, T. M., Fodor, I., and Slater, J. M. TNF-α Gene and Proton Radiotherapy in an Orthotopic Brain Tumor Model. Int. J. Oncol. 21, 251-259 (2002).
55. Gridley, D. S., Li, J., Kajioka, E. H., Dutta-Roy, R., Andres, M. L., Timiryasova, T. M., and Fodor, I. Lymphocyte Activation with Localized pGL1-TNF-α Gene Therapy in a Glioma Model. Oncology 62, 66-77 (2002).
56. Gridley, D. S., Timiryasova, T. M., Miller, G. M., Andres, M. L., Dutta-Roy, R., Bayeta, E. J., and Fodor, I. Evaluation of TNF-α/Bax Gene Therapy and Radiation Against C6 Glioma Xenografts. Technol. Cancer. Res. Treat. 2, 41-50 (2003).
57. Li, J., Andres, M. L., Fodor, I., Nelson, G. A., and Gridley, D. S. Evaluation of pGL1-TNF-α Therapy in Combination with Radiation. Oncol Res. 10, 379-387 (1998).
58. Kawase, A., Nomura, T., Yasuda, K., Kobayashi, N., Hashida, M., and Takakura, Y. Disposition and Gene Expression Characteristics in Solid Tumors and Skeletal Muscle After Direct Injection of Naked Plasmid DNA in Mice. J. Pharm. Sci. 92, 1295-1304 (2003).
59. Nomura, T., Nakajima, S., Kawabata, K., Yamashita, F., Takakura, Y., and Hashida, M. Intratumoral Pharmacokinetics and In Vivo Gene Expression of Naked Plasmid DNA and its Cationic Liposome Complexes After Direct Gene Transfer. Cancer Res. 57, 2681-2686 (1997).
60. Yang, J. P. and Huang, L. Direct Gene Transfer Too Mouse Melanoma by Intratumor Injection of Free DNA. Gene Ther. 3, 542-548 (1996).
61. Hanna, N. N., Seetharam, S., Mauceri, H. J., Beckett, M. A., Jaskowiak, N. T., Salloum, R. M., Hari, D., Dhanabal, M., Ramchandran, R., Kalluri, R., Wukhatme, V. P., Kufe, D. W., and Weichselbaum, R. R. Antitumor Interaction of Short-course Endostatin and Ionizing Radiation. Cancer J. 6, 287-293 (2000).
62. Shi, W., Teschendorf, C., Muzyczka, N., and Siemann, D. W. Gene Therapy Delivery of Endostatin Enhances the Treatment Efficacy of Radiation. Radiother Oncol. 66, 1-9 (2003).